Clinical Trial: Tocilizumab for Acute Chest Syndrome
Study Status: Completed
Recruit Status: RECRUITING
Condition: Sickle Cell Disease
Study Type: INTERVENTIONAL
Official Title: Low-Dose Tocilizumab for Acute Chest Syndrome in Sickle Cell Disease
Brief Summary:
The investigators are evaluating the role of a low dose of tocilizumab in treating acute chest syndrome in patients with sickle cell disease.Tocilizumab inhibits interleukin-6 (IL-6) receptors and is used to treat rheumatoid arthritis and severe cytokine release syndrome, which can be seen with chimeric antigen receptor T-cell (CAR-T) therapy, and it is also authorized for treatment of COVID-19.Since IL-6 levels are elevated in the sputum of patients with acute chest syndrome, the investigators are hopeful that…
Read more